MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.
Epistemonikos ID: d94bca60e85a39f753cc7496d5252b25c557c5ab
First added on: May 20, 2024